If you have diabetes or prediabetes, a sermorelin consultation needs to include your blood sugar history. A promise of better metabolism does not establish that a treatment will improve glucose control, and a medicine that influences growth hormone deserves a careful discussion with the clinician managing your diabetes.

There is no reliable percentage on this page for your chance of developing high blood sugar from a particular compounded prescription. The available sources involve different medicines and patient groups. They explain why monitoring matters, but they cannot replace an assessment of your own health and treatment.

The considered take

Coordinate the decision with your diabetes clinician. Do not assume that a growth hormone treatment will lower blood sugar.

Why growth hormone is relevant to glucose

Growth hormone participates in the body's handling of energy. NIDDK describes altered glucose processing and possible type 2 diabetes in acromegaly, a condition involving excessive growth hormone. That is useful biological context, but acromegaly is not the same exposure as a prescribed sermorelin preparation.

Another relevant source is the tesamorelin prescribing information, which calls attention to glucose intolerance and diabetes. Tesamorelin is a different medicine. Neither source establishes that all sermorelin users will develop diabetes, nor that a normal starting glucose makes treatment risk-free. The appropriate conclusion is to evaluate the concern, not to copy a risk percentage from another condition.

Sources: NIDDK: Acromegaly · DailyMed: EGRIFTA WR prescribing information

Bring the information your care team can actually use

Prepare your recent glucose or A1c results, current diabetes medicines, and any home-monitoring records you already keep. Include episodes of low blood sugar, recent illness, changes in appetite or weight, and the date of any medication change. Do not start extra testing solely to satisfy an online checklist without discussing what is needed.

Ask who will review results if two different services are involved. A telehealth platform may not automatically receive records from your usual clinician. Our laboratory guide explains why IGF-1 is only one part of a broader assessment; it does not substitute for diabetes monitoring.

Sources: FDA: Managing the benefits and risks of medicines · Endocrine Society: Adult growth hormone deficiency

A GLP-1 medicine does not cancel another drug’s risks

Taking semaglutide, tirzepatide, insulin, or another glucose-lowering medicine does not establish that adding sermorelin is suitable. Combining treatments creates its own question: what benefit is expected, what may change, and who will adjust care if needed?

Do not lower, stop, or increase a diabetes medicine to make room for a peptide regimen. Give both prescribers the complete ingredient list, including any blend. The GLP-1 combination article helps separate weight-management evidence from claims made for an added peptide.

Sources: FDA: Drug interactions, what you should know · NIDDK: Prescription medications for weight management

Agree on a response plan before a refill

Ask which measurements matter for you, when they should be reviewed, and which changes should prompt a call. Use your established diabetes action plan for out-of-range readings or symptoms; do not wait for a routine peptide refill to raise a concern.

A useful question is: “If my glucose worsens without a meaningful improvement in the symptom we are treating, what would we reconsider?” The answer should be more specific than continuing until a marketing timeline has elapsed. Bring that question to the consultation checklist and make sure the relevant clinicians can communicate.

Sources: FDA: Managing the benefits and risks of medicines · DailyMed: EGRIFTA WR prescribing information

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. NIDDK: AcromegalyNIH patient education · Explains effects of pathological GH excess; does not estimate diabetes risk from prescribed sermorelin.
  2. DailyMed: EGRIFTA WR prescribing informationClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
  3. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
  4. Endocrine Society: Adult growth hormone deficiencyClinical practice guideline · Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
  5. FDA: Drug interactions, what you should knowUS regulator · General medicine, food and supplement interaction principles, not an exhaustive sermorelin interaction list.
  6. NIDDK: Prescription medications for weight managementClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.